91 related articles for article (PubMed ID: 23219704)
1. Slow dissolution behaviour of amorphous capecitabine.
Meulenaar J; Beijnen JH; Schellens JH; Nuijen B
Int J Pharm; 2013 Jan; 441(1-2):213-7. PubMed ID: 23219704
[TBL] [Abstract][Full Text] [Related]
2. Development of an extended-release formulation of capecitabine making use of in vitro-in vivo correlation modelling.
Meulenaar J; Keizer RJ; Beijnen JH; Schellens JH; Huitema AD; Nuijen B
J Pharm Sci; 2014 Feb; 103(2):478-84. PubMed ID: 24311366
[TBL] [Abstract][Full Text] [Related]
3. Novel interpenetrating network chitosan-poly(ethylene oxide-g-acrylamide) hydrogel microspheres for the controlled release of capecitabine.
Agnihotri SA; Aminabhavi TM
Int J Pharm; 2006 Nov; 324(2):103-15. PubMed ID: 16824710
[TBL] [Abstract][Full Text] [Related]
4. Trichotomous gastric retention of amorphous capecitabine: an attempt to overcome pharmacokinetic gap.
Singh Y; Singh M; Meher JG; Pawar VK; Chourasia MK
Int J Pharm; 2015 Jan; 478(2):811-21. PubMed ID: 25529434
[TBL] [Abstract][Full Text] [Related]
5. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the capacity of low glass transition temperature excipients to minimize amorphization of sulfadimidine on comilling.
Curtin V; Amharar Y; Hu Y; Erxleben A; McArdle P; Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2013 Jan; 10(1):386-96. PubMed ID: 23186332
[TBL] [Abstract][Full Text] [Related]
7. Lamellar crystalline self-assembly behaviour and solid lipid nanoparticles of a palmityl prodrug analogue of Capecitabine--a chemotherapy agent.
Gong X; Moghaddam MJ; Sagnella SM; Conn CE; Danon SJ; Waddington LJ; Drummond CJ
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):349-59. PubMed ID: 21477999
[TBL] [Abstract][Full Text] [Related]
8. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
Dengale SJ; Ranjan OP; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Sci; 2014 Oct; 62():57-64. PubMed ID: 24878386
[TBL] [Abstract][Full Text] [Related]
10. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
Maghsoodi M; Sadeghpoor F
Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
[TBL] [Abstract][Full Text] [Related]
11. Cocrystallization and amorphization induced by drug-excipient interaction improves the physical properties of acyclovir.
Masuda T; Yoshihashi Y; Yonemochi E; Fujii K; Uekusa H; Terada K
Int J Pharm; 2012 Jan; 422(1-2):160-9. PubMed ID: 22079714
[TBL] [Abstract][Full Text] [Related]
12. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
[TBL] [Abstract][Full Text] [Related]
13. Crystal growth formation in melt extrudates.
Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
[TBL] [Abstract][Full Text] [Related]
14. Formulation, characterization, and in vitro evaluation of bioadhesive gels containing 5-Fluorouracil.
Dhiman M; Yedurkar P; Sawant KK
Pharm Dev Technol; 2008; 13(1):15-25. PubMed ID: 18300096
[TBL] [Abstract][Full Text] [Related]
15. Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form 1.
Chieng N; Zujovic Z; Bowmaker G; Rades T; Saville D
Int J Pharm; 2006 Dec; 327(1-2):36-44. PubMed ID: 16949221
[TBL] [Abstract][Full Text] [Related]
16. Study on formulation variables of methotrexate loaded mesoporous MCM-41 nanoparticles for dissolution enhancement.
Vadia N; Rajput S
Eur J Pharm Sci; 2012 Jan; 45(1-2):8-18. PubMed ID: 22067974
[TBL] [Abstract][Full Text] [Related]
17. Preparation and evaluation of metastable solid-state forms of lopinavir.
Lemmer HJ; Liebenberg W
Pharmazie; 2013 May; 68(5):327-32. PubMed ID: 23802429
[TBL] [Abstract][Full Text] [Related]
18. Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form.
Ambrogi V; Perioli L; Marmottini F; Rossi C
Eur J Pharm Biopharm; 2007 May; 66(2):253-9. PubMed ID: 17123798
[TBL] [Abstract][Full Text] [Related]
19. The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin.
Priemel PA; Grohganz H; Gordon KC; Rades T; Strachan CJ
Eur J Pharm Biopharm; 2012 Sep; 82(1):187-93. PubMed ID: 22683936
[TBL] [Abstract][Full Text] [Related]
20. Formulation, development and in vitro characterization of modified release tablets of capecitabine.
Gaikwad SS; Avhad RD; Kalkotwar RS
Drug Dev Ind Pharm; 2020 Jan; 46(1):20-30. PubMed ID: 31778085
[No Abstract] [Full Text] [Related]
[Next] [New Search]
